Uncategorized
- Life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) specializes in the use of ultra-high pressure technologies to innovate unexpected and potent solutions for a wide variety of industries, including biomarker and target discovery, forensics, counter-bioterror applications, improved quality and economics for biopharmaceuticals, and safer, more potent and more cost-effective, storage, dosing and absorption of nutrients, nutraceuticals, cosmeceuticals, agrochemicals for plants, and more
- Pressure BioSciences recently announced the development of extraordinarily effective dosing and delivery in uniform nanoemulsions of 30 to 60 nm droplets for the powerful antioxidant astaxanthin (“AsX”), and suitable for many other prospective nutraceuticals
- PBIO’s technology for nanoemulsions commands extremely high commercial appeal because of its ability to dramatically improve the entire sensory profile of many retail products, while simultaneously improving the economics for producers and/or consumers, and making medicines and nutraceuticals safer, more easily absorbed, and more bioavailable within targeted humans, animals and plants
- Their breakthrough achievement in AsX nanoemulsions is simply the demonstration gateway to the potential production of an enormous range of more bioavailable, higher quality fat-soluble vitamins, nutraceuticals and dietary supplements
- Preorders for its first dozen commercial nanoemulsion production systems are converting into PBIO’s powerful new leasing and royalty driven business model, with initial, solid incremental revenue expected in early 2022
The development of the oil-soluble antioxidant astaxanthin as an extremely fine and uniform nanoemulsion that easily disperses and effectively dissolves into water with intrinsic stability, was announced July 1, and launches a revolutionary new growth phase for life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) and its trademarked Ultra Shear Technology(TM) (“UST”) platform.
Pressure BioSciences (also known as PBI) has developed its UST platform to apply ultra high pressure and intense shearing forces for the innovative production of a unique class of high-quality nanoemulsions that offer enormous new benefits in a wide variety of industries, including the nutraceuticals market, which is expected to powerfully leverage the benefit of the astaxanthin nanoemulsions development, into a plethora of other newly differentiated nutraceutical products.
Astaxanthin, or AsX, is renowned as an antioxidant 6000 times more powerful than vitamin C that has been shown clinically to enhance the human body’s natural immune response, improve muscle endurance in exercise, support cardiovascular, brain and eye health, protect skin against UV damage, and beneficially modify cell signaling pathways that promote cancer cell death, according to Pressure BioSciences’ news release (https://ibn.fm/pKhEn).
Because AsX is essentially water-insoluble, the body’s ability to absorb it rather than simply passing it through to excretion has been measured at typically less than 10 percent of the amount of ingested or topically applied compound. The nanoemulsion developed through the UST pressure and shearing IP has the potential to make AsX more easily and fully absorbed and bioavailable, and thus more effective with lower dosing and improved economics for the producer and/or the consumer. Similar benefits for other carotenoids and a wide range of fat-soluble vitamins, nutraceuticals, dietary supplements are anticipated, and will extend into agrochemicals, cosmeceuticals and personal care products, and other industries.
“Nanoemulsions produced by PBI’s UST platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter” PBI Senior Research Scientist Gary B. Smejkal stated in the news release. “The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published.”
Pressure BioSciences anticipates the use of its technology will make it possible for nutraceutical companies to exercise greater control over their dosing and find ways to lower their costs, which may in turn lower the costs for consumers. The pressure-shearing process also reduces the need for large amounts of added chemicals used currently in chemically produced nanoemulsions.
“The global astaxanthin market size was estimated at USD 1.0 billion in 2019,” PBI President and CEO Richard T. Schumacher stated. “PBI is laser-focused on exploring the opportunities for our UST platform to profoundly alter the effectiveness and competitiveness of a great number of lucrative nutraceutical products. We have already begun discussions with prospective partners worldwide who are interested in using UST for production and commercialization of astaxanthin and other nutraceutical nanoemulsions.”
The company has received pre-orders for 12 BaroShear K45 systems, the company’s first commercial application of its UST-based processing system, and expects to be able to fulfill the orders beginning late this year through a lease/royalty business model, which it expects to generate up to $3 million in incremental revenue in late 2021 and early 2022 (https://ibn.fm/AXJlp).
Pressure BioSciences boasts an intellectual property portfolio already including more than 25 patents worldwide and is advancing rapidly towards inflections into significantly increased revenues and profitability. In addition to the nutraceuticals nanoemulsions market, the company’s primary focus includes pressure-based technology development of products for biomarker and target discovery, improved soil and plant biology, forensics, counter-bioterror applications, and improved quality and economics for biopharmaceuticals.
For more information, visit the company’s website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29) CEO and founder Evan Gappelberg will be presenting live at VirtualInvestorConferences.com. Gappelberg’s presentation is scheduled for Aug. 5, 2021, at 9:30 a.m. ET. The company, a diversified leading provider of augmented reality (“AR”) solutions and services, has invited investors, advisors and analysts to attend the real-time, interactive presentation. Those attending will be able to ask questions in real time. An archived webcast of the presentation will also be available after the event for interested parties who are unable to attend. A leading proprietary investor conference series, Virtual Investor Conferences (“VIC”) provide an interactive forum for publicly traded companies to meet and present directly with investors.
To register for the event, visit https://ibn.fm/UkYg3
To view the full press release, visit https://ibn.fm/z9hhp
About Nextech AR Solutions Corp.
Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360-degree portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.
Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). For more information about the company, please visit www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Over the next few decades, electric vehicles (“EVs”) are expected to replace the petrol and diesel-powered cars that have been a staple on the roads for more than a century. Anyone who’s aware of battery electric vehicles (“BEVs”) has probably heard that they are cheaper to maintain. But how exactly does one maintain an electric car over its lifetime? And why are these maintenance costs said to be less compared to conventional vehicles? Let’s take a look.
Rather than an internal combustion engine, electric vehicles are powered by a rechargeable lithium-ion battery pack, which will require less maintenance. Compared to a conventional car, an EV has significantly fewer moving parts, around 20 to be exact, while a gasoline or diesel-powered car has a whopping 2,000, representing numerous points of possible failure. As EVs have significantly fewer moving parts, owners don’t have to visit a mechanic regularly to make sure those parts are all functioning properly.
The vehicles also don’t require oil, so owners won’t have to make the four or so annual visits to the mechanic for oil changes, saving both time and money. Consequently, EV maintenance costs will be significantly less by virtue of having fewer parts to maintain. However, EV owners will still have to keep an eye on the brakes, tires, airbags, steering and suspension, windshield wipers and fluids, and cabin air filters.
Owners will need to make sure the tires are fully inflated and check for wear and tear as needed. They will need to do the same with the windshield wiper fluid, filling it up when necessary. Every 7,500 miles or so, an EV should be taken to a certified EV mechanic to ensure its components are in good shape. The mechanic will check for fluid leaks in the battery coolant heater, power inverter, accessory power and charge modules; they will also inspect the half-shafts, driveshafts, power steering, accelerator pedal, airbag system, gas struts (suspension), and body components for any damage and make the appropriate repairs.
The battery, which is the most important part of the EV, will also require extra care to ensure it charges and discharges energy efficiently for a long time. For starters, watch out for extreme heat and cold as temperatures will affect a battery’s range and longevity. If owners are able, they should park their vehicles in garages or under shade during extreme heat and park the cars in the sun when it gets too cold.
Charging habits will also affect the battery, so owners should be sure to keep levels under 75% to 80% while not letting levels get below 15% to 20%. Additionally, it is recommended that owners use fast charging only occasionally as it can strain the battery and cause it to degrade.
If it is within an owner’s budget, it is ideal to install a Level 2 charger at home and charge the EV overnight. Trickle and timed chargers are also recommended as they can charge an EV slowly and keep the battery from wearing down too quickly. With American drivers totaling an average of 25.9 miles per day, most drivers won’t need to use a fast charger unless they are taking a long trip.
At the end of the day, an EV does still need maintenance, but generally that maintenance involves less time at the mechanic and less strain on a wallet.
Needless to say, individual sector players such as Net Element (NASDAQ: NETE) are likely to avail specific maintenance information on the models that they release onto the market, and that information can be helpful in preventing the premature aging of EVs.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a new provisional patent application to protect its proprietary digital therapeutics platform; the patent is the company’s 13th. In addition, the company is also advancing the build-out of its digital therapeutics strategy, with the objective of evolving its programs beyond the psychedelic molecule into an eco-system with potential to improve patient treatments. A newly formed patient steering company is part of the company’s focus on its digital therapeutics platform, designed to better support the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for improved pre- and postpsychedelic treatments. In the announcement, the company stated that the aim of utilizing and leveraging cutting-edge technologies to support drug-development candidates is one of its top priorities.
To view the full press release, visit https://ibn.fm/j1QGQ
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
A recent study by the St. Jude Children’s Research Hospital and the School of Medicine at the Washington University in St. Louis proposes that young patients with an average risk medulloblastoma can, after a six-week radiation treatment regimen, undergo a radiation boost to a smaller area of the brain.
Medulloblastoma is a pediatric brain cancer that usually affects the spine and/or brain and can spread through a patient’s spinal fluid. The standard of care for this type of cancer includes radiation therapy to the whole spine and brain, after which an extra dose of radiation to the back of the brain is administered in order to prevent the spread of the cancer.
While this is the standard treatment, the radiation utilized in the treatment of these tumors damages cognitive function, particularly in young patients whose brains are still in the early development stages.
Researchers believe that preventive radiation treatment doses that are administered to the patient’s spine and brain over the six-week course cannot be decreased with diminishing survival. In their study, the researchers found that each patient’s cancer responded differently to treatments, noting that this was dependent on the tumors’ biology, which sets the stage for future trials of targeted therapies. The study’s findings were reported in the “Journal of Clinical Oncology.”
Patients with pediatric average risk medulloblastoma have five-year survival rates of 75–90%. Contrastingly, those suffering from high-risk medulloblastoma have five-year survival rate of 50–75%. Factors such as tumor spread and the age of a child are also considered in determining each patient’s risk category.
For their research, scientists focused on patients suffering from average-risk medulloblastoma. They evaluated more than 400 patients, between the ages of 3 and 21, who were diagnosed with the aforementioned cancer. Patients aged between 3 and 7 were randomly assigned to receive either low-dose or standard-dose radiation to the spine and head region in every treatment given over the six-week period. Patients above this age received the standard dose, as their brain development isn’t as vulnerable to radiation.
Prof. Jeff M. Michalski of radiation oncology noted that the objective of the study was to see if the amount of radiation could safely be reduced without affecting the treatment’s efficacy. The researchers discovered that while decreasing the radiation dose over the six-week treatment period negatively affected survival, it was also possible to safely decrease the volume size of the brain that received the radiation boost at the end of the treatment period. Michalski hopes that these measures may assist in the reduction of the treatment’s effects, particularly in younger patients.
Some companies, such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are also working to come up with better remedies for cancers affecting the brain or central nervous system, and these novel treatments could offer superior clinical outcomes.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin
- This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy
- The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes
- XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023
For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the company and a significant milestone for its rapid point-of-care (“POC”) diagnostic business strategy.
XPhyto describes Covid-ID Lab as a “25-minute testing revolution” (https://ibn.fm/4erIO). It is specifically designed to offer reliable Covid-19 test results in under 25 minutes while offering various other benefits, including eliminating unnecessary quarantine restrictions. With this test, XPhyto also promises to increase safety in schools, medical centers and other government services and facilitating rapid airport, border and cruise ship testing to minimize travel risk.
Summer is usually the high travel season. With the Covid-19 outbreak, there has been a surge in demand for reliable and rapid testing. XPhyto acknowledges this demand and plans on capitalizing on it with its Covid-ID Lab kit, the fastest PCR system in the world, according to XPhyto’s Chief Executive Officer (“CEO”), Hugh Rogers.
“Our portable Covid-ID Lab is designed to be one of the fastest PCR systems in the world, while our platform is economic at low to mid-range sample volumes,” said Hugh Rogers, the CEO and director of XPhyto. “We anticipate strong and sustainable demand for our rapid and versatile PCR system and look forward to further expanding our reach,” he added (https://ibn.fm/sgnkA).
XPhyto Therapeutics Corp. is a bioscience accelerator focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its profile currently falls under three broad categories: diagnostics, drug delivery, and drug development (https://ibn.fm/GJn0r). For drug development, XPhyto focuses on four late-stage neurology therapeutics within clinical development, along with two other psychedelic medicine programs. For its drug delivery program, XPhyto has a platform technology already in place. It is designed to develop innovative, cost-effective transdermal and oral dissolvable formulations of hybrid-generic, generic and new active pharmaceutical ingredients.
XPhyto’s diagnostics lead product is the rapid POC COVID-19 RT-PCR diagnostic test, which launched in Europe in April 2021. The goal for the entire program is to develop real-time ultra-low-cost infectious disease biosensors and making tests, particularly Covid-19 PCR tests, fast and affordable.
With the growing requirement for PCR tests for travelling, XPhyto recognizes the tremendous potential for rapid PCR checks from a commercial standpoint.
“Rapid, reliable and decentralized PCR tests are exactly what the market needs right now; precisely because incidence rates are falling and therefore sample numbers are decreasing,” noted Michael Kretzer, the CEO of Max Pharma, XPhyto’s distribution partner and pharmaceutical wholesaler (https://ibn.fm/dDOjN). “There will be areas of application where rapid, reliable, and universally recognized results are always required. Accordingly, we see a specialized and sustainable opportunity for the Covid-ID and anticipate a steep order volume uptake in the near future,” he added.
Covid-ID Lab represents a significant shift from conventional PCR testing models. Typically, samples collected are shipped to large centralized and automated labs for processing. This has been known to not only take time but also be expensive (https://ibn.fm/4RMhK). XPhyto seeks to address this with its decentralized testing model. It projects that it will yield faster results, more versatile test center options and, most importantly, cost-effectiveness at lower testing volumes.
The deployment of the 1000 Covid-ID Lab test kits marks the start of a short trial period for integrating and evaluating XPhyto’s new PCR test system. The entire process is designed so that sample processing will occur directly at the sample collection site. The data collected will allow the company to launch the product successfully in other locations across Europe.
XPhyto continues to innovate and grow its three key sectors. With the deployment of its Covid-ID Lab, the company aims at capitalizing on the rapid test market that is projected to reach $39.1 billion by 2023, representing a compound annual growth rate (“CAGR”) of 8.9% between 2021 and 2023. The two other aspects of XPhyto’s diagnostic pipeline include the Peptide biosensor for infectious diseases and the Peptide biosensor for oral health, both of which are still in their design and development stages.
For more information, visit the company’s website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
TAAT(TM) Global Alternatives’ (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) has announced that its game-changing tobacco-free and nicotine-free product is now being sold in the state of Illinois. The availability of TAAT(TM) by 19 tobacco retailers across the state complements new launch initiatives announced by the company for Georgia, North Carolina, South Carolina and Alabama. According to the announcement, Illinois has a smoking incidence rate of 15.5% among adults with a total population of 12.67 million, representing a significant opportunity for TAAT to expand its presence in the Midwest. With these new retail locations, TAAT is now available in more than 300 stores across the United States; the product is also available online. “The opportunity for TAAT in Illinois is significant as there are well over one million smokers aged 21-plus in the state, many of whom reside in Cook County and are subjected to the highest tax burden in the nation when it comes to buying tobacco cigarettes,” said TAAT CEO Chief Setti Coscarella in the press release. “Right from the beginning, we have placed TAAT in 19 tobacco retailers across the state, which we intend to leverage along with existing online demand in Illinois to further penetrate this market. We conducted consumer research earlier this year with smokers aged 21-plus in markets to include Illinois, and nearly two-thirds of respondents who stated their desire to leave nicotine behind specified that the cost of smoking tobacco cigarettes was a contributing factor to this desire. We are pleased to be making a better alternative to tobacco cigarettes available at a price point that is less than half what the average pack of tobacco cigarettes costs in Ohio, as we broaden our initiatives to capture market share in the USD $814 billion global tobacco industry.”
To view the full press release, visit https://ibn.fm/8cgKl
About TAAT Global Alternatives Inc.
TAAT Global Alternatives has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, will be releasing two financial reports by the end of the month. The company announced plans to report its numbers for FY 2020, the fiscal year ended Dec. 31, 2020, after market close on July 22, 2021; the company will also release its third-quarter financial report for the period ended March 31, 2021, after market close on July 26, 2021. In addition, the company announced plans for a management conference call, scheduled for July 27, 2021, at 4:30 p.m. ET. More details regarding the call and how to participate will be released on July 22. In recent weeks, the company has replaced its previous auditor, MNP LLP, because of health issues with the auditor’s lead engagement partner. The company commended Macias Gini & O’Connell LLP, the new auditor, for its efforts in “completing an exceptionally complex and challenging audit with a very tight timeline,” according to the announcement. “The delay in completing the filing of the cocuments was due to MNP not completing its audit procedures in advance of the filing deadline.”
To view the full press release, visit https://ibn.fm/pqWny
About Red White & Bloom Brands Inc.
Red White & Bloom Brands is positioning itself to be one of the top-three, multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on major U.S. markets, including Michigan, Illinois, Massachusetts, Oklahoma, Florida, Arizona and California, with respect to cannabis, as well as the United States and internationally for hemp-based CBD products. For more information about the company, please visit www.RedWhiteBloom.com.
NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced enhancement of its offerings with the addition of vegan wine to its expanding product selection on its U.S. e-commerce platform. The company is adding a curated selection of high-quality vegan wines, by brands such as Rare Earth, Veuve Clicquot, Pino Cellars and Gravel Bar Winery, with new items now available to order in the “Plant-Based Wine” section of PlantX’s U.S. platform. “The alcoholic beverage market is one of the fastest growing industry segments in the U.S. and globally,” said PlantX CEO Julia Frank. “The new vertical will allow PlantX to holistically meet customer demands and expectations by expanding its product offerings in line with its mission and values.”
To view the full press release, visit https://ibn.fm/48jLd
About PlantX Life Inc.
As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at www.PlantX.com and the PlantX investor website at https://Investor.PlantX.com.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a provider of virtual and augmented reality (“AR”) experience technologies and services for e-commerce, education, advertising, conferences, and events, jointly received government funding of up to $150,000 alongside Ryerson University. The amount, awarded by the Virtual Learning Strategy’s eCampusOntario (an initiative of the Ontario Ministry of Colleges and Universities), was in recognition for the partners’ efforts in creating and delivering AR learning experiences within the postsecondary education sector. A recent article quotes Nextech CEO Evan Gappelberg as saying, “With the help of the Ontario Government — who shares our vision of augmented reality, immersive learning — we are delivering on our goal to transform higher education.” The article further reads, “Hailing AR and education as a perfect marriage, Evan went on to explain that this combination is bound to play a vital role in learning environments globally, especially given that AR solutions have continued gaining traction in multiple industries.”
To view the full article, visit https://ibn.fm/AFndT
About Nextech AR Solutions Corp.
Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360° portals to its audiences, altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences. Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three ecommerce platforms, VacuumCleanerMarket.com (“VCM”), InfinitePetLife.com (“IPL”) and TruLyfeSupplements.com (“TruLyfe”), as well as VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, visit www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
After more than a century of dominating the roads, internal combustion engines (“ICE”) seem to be on the way out. ICE vehicles, especially passenger vehicles, are responsible for close to 30% of global carbon emissions. As climate change accelerates and the planet heats up, zero-emission electric vehicles (“EVs”) have been crowned the successor of the internal combustion engine.
However, EVs still make a small percentage of global vehicle sales, a paltry 4% to be exact, with most drivers opting for tried and tested petrol and diesel-powered cars. They can take hours to fully charge, and an insufficient and often unreliable network of public charging stations has kept plenty of drivers from switching to electric vehicles. Fast-charging technology is one of the best ways to allay range anxiety, and a new ultra-fast charger from Nidec Industrial Solutions may be what the industry needs to supercharge EV adoption.
Nidec Industrial Solutions has installed an ultra-fast charging station on an Italian state highway that is capable of supplying up to 320 kW of power to a single vehicle. In addition, it can be connected to both MV and LV grids. Consequently, it can charge electric vehicles to 80% in less than 15 minutes. Additionally, it does so without placing a significant strain on the electricity grid, which will have to be beefed up in the coming years to support a mass shift to electric cars.
Installed along Telesina state highway 372, the ultra-fast charging station, which features the most advanced, new-generation, ultra-fast chargers in the market, will be a godsend for drivers taking long trips using that route. Due to its compact size, the new ultra-fast charging system can be distributed to other regions to meet the demand for fast-charging infrastructure. Were other countries to adopt such ultra-fast charging technology, they would be able to develop a widespread network of fast chargers, eliminating one of the main obstacles to mass EV adoption.
Range anxiety has been a major hindrance to electric vehicle adoption in most cities and countries. Although most drivers generally drive an average of 25 miles a day, they would still prefer a vehicle that can allow them to take longer trips without any anxiety. Installing ultra-fast charging stations such as Nidec’s along highways would not only ease drivers’ fears of running out of power without a charging station in sight, but it would also allow those drivers to recharge their vehicles in a relatively short time and be on their way.
To avoid straining the national grid too much and forcing energy providers to use more fossil fuels to generate electricity, Nidec’s ultra-fast charging stations employ battery energy storage.
Moving forward, developing a network of ultra-fast charging stations that can charge numerous types of vehicles, from passenger cars and buses to commercial vehicles, using mostly clean energy could be one of the only ways to increase EV adoption. For-profit companies such as Ideanomics Inc. (NASDAQ: IDEX) have realized this need and are providing wireless charging facilities geared at commercial vehicles. This will increase EV adoption in this market segment and the industry in general.
NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
- HempFusion Wellness closed the acquisition of Sagely Naturals, a women-centric CBD company, for an initial consideration of US$25 million in cash and stock payments
- The acquisition is expected to benefit both parties in various ways, including by increasing HempFusion’s revenue and providing access to Sagely’s extensive distribution footprint
- On its part, Sagely will benefit from HempFusion’s regulatory compliance, which will help in the introduction of ingestible CBD products
- HempFusion is looking forward to driving shareholder value through continued growth both domestically and internationally with its expanding family of brands
In fulfillment of a merger agreement announced in late May, Denver-based leading health and wellness company HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 800) completed the acquisition of premier women-centric CBD brand Sagely Enterprises Inc. (“Sagely Naturals”) on July 7 (https://cnw.fm/86bVZ). The purchase, which made Sagely Naturals a wholly owned subsidiary of HempFusion Wellness, is expected to benefit both parties.
Boasting an extensive retail distribution footprint of 14,000+ stores in the United States, Sagely Naturals is the third most successful brand, leading CBD topicals brand, and largest women-founded CBD company in the industry. This market position is reflected in its financials for the fiscal year 2020, in which it reported net revenue of over $4.19 million.
The now wholly owned subsidiary provides HempFusion with immediate distribution to up to 14,000 additional stores as well as a significant increase in revenue. In fact, when combined with the closing of APCNA Holdings LLC’s (“Apothecanna”) purchase agreement, announced May 17, HempFusion’s 2020 revenue will more than triple. Both acquisitions further offer the opportunity to expand this revenue well into the future.
In an interview with Proactive (https://cnw.fm/SZCRE), HempFusion CEO Jason Mitchell, N.D., noted that while Sagely Naturals does not offer ingestible CBD products at the moment, HempFusion’s focus on being regulatorily compliant will allow it to install a completely new ingestible program for them. This will provide an opportunity to introduce ingestible CBD products in up to 14,000 stores. “So, we are going to give them near-immediate expansion into new products they haven’t had previously,” said Mitchell.
HempFusion’s significant investment into regulatory compliance will help solidify Sagely Natural’s leadership position in the CBD industry. HempFusion has also included Sagely Naturals on its Novel Foods Application Dossier with the United Kingdom’s Regulatory Food Safety Agency to aid in future expansion into Europe.
Additionally, as both companies have complementary product offerings that do not directly compete, the acquisition offers substantial cross-platform opportunities through each of their respective distribution channels.
“Integration has been well underway over the past several weeks, and we look forward to driving shareholder value through continued growth in 2021 and 2022 both domestically and internationally with our expanding family of brands,” stated Mitchell in a press release.
HempFusion closed the acquisition for an initial consideration of US$25 million, of which $2 million was paid in cash (subject to adjustment for Sagely Naturals’ cash and working capital), and the balance was satisfied by the issuance of more than 22.5 million common HempFusion shares. You can find a comprehensive description of the terms of the acquisition in the press release.
In the Proactive interview, Mitchell held that M&A remains a vital part of the company’s future. Thus, the recent acquisition of Sagely Naturals “is certainly not going to be our last.”
For more information, visit the company’s website at www.HempFusion.com/corporate-information.
NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://cnw.fm/CBDHF
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
FingerMotion (OTCQX: FNGR) is anticipating significant growth in mobile service sales during the coming year. “The company’s focus on rich communication services (‘RCS’) and data insights in China’s huge marketplace for mobile products has positioned the U.S.-based company for growth in the insuratech industry, particularly, where it anticipates acquiring service for more than a billion customers in the Southeast Asian Nation,” reads a recent article. The company is leveraging partnerships to build a communications ecosystem of active users of its innovative applications and expects to develop access to users’ data to strengthen its Sapientus database IP. Sapientus has already led to a landmark agreement with Pacific Life Re-insurance to help the company enhance its insurance solutions among Chinese clients and develop predictive consumer information that can serve as a substitute for a credit score system where a standard for such a system doesn’t already exist. In reporting the company’s year-end financial position, CEO Martin Shen stated: “We are a technology company and believe our future lies in the Big Data Insights division. By the end of calendar 2021, we expect multiple contracts relating to our Insuratech products.”
To view the full article, visit https://ibn.fm/eLzpc
About FingerMotion Inc.
FingerMotion is an evolving technology company with core competencies in mobile payment and recharge platform solutions in China. It is one of only a few companies in China with access to wholesale rechargeable minutes from the country’s largest mobile phone providers that can be resold to consumers. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. FingerMotion’s vision is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high-engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve over 1 billion users in China and eventually expand the model to other regional markets. For more information about the company, visit www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at http://ibn.fm/FNGR
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer
ChineseWire
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
Fitch Solutions recently released a report that shows that the production growth of copper and gold across the globe is set to resume determinedly as the disruptions that have affected mines in the last year are halted. In the period 2012–2025, Fitch expects that the global mine production growth will stay strong as rising prices encourage more output and investments.
The company also predicts that the production of gold across the globe will increase from about 109 million ounces this year to roughly 141 million ounces by the year 2030 at an annual growth rate of 3.2%. According to this analytics company, this indicates an advance in the 0.8% average growth rate recorded in the 2016–2020 period.
The report notes that in the coming decade, the output of gold in China will stagnate after increasing during the last ten years. Additionally, reducing ore grades will curb domestic investment, which will in turn push more Chinese companies to develop projects overseas. Leading Chinese companies are expected to increase their investments in foreign gold mines as the nation’s demand for gold surpasses production.
Major deals in the last few years around the world include the $960 million purchase of a 50% stake in Barrick Gold’s Argentinian Veladero mine by Shandong Gold. Analysts anticipate that the companies will also collaborate on exploration activities in the region. Earlier in 2017, Zijin Mining produced just over a million ounces of gold, which made up roughly 10% of China’s total gold output.
Over in Australia, the gold sector is expected to record a production growth in the near future, which will be backed by competitive operating costs, increasing prices of gold and a robust project pipeline. Fitch predicts that Australia’s gold production will increase to roughly 13 million ounces by 2030 from about 10 million ounces this year. This increase equates to a 2.2% annual growth rate. With regard to copper, Fitch anticipates that the international production of copper will increase by nearly 8% year-on-year as new projects begin.
The company expects the output of copper to remain steady over the medium term as more companies begin expansions and more projects are begun. Fitch also notes that the increasing demand for the red metal and increasing prices will allow it to remain strong. Fitch predicts that the production of copper will also grow by an average rate of 3.7% annually, increasing from roughly 20 million tons last year to about 29 million tons in 2030.
This bullish forecast could spur on mining companies such as Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) that currently have precious metals exploration as well as development projects going on at different resource-rich properties.
NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at https://ibn.fm/EXN
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
New research conducted by a group of scientists from Finland and the UK, led by a team from University of Birmingham, has found that children who experience cognitive difficulties such as a lack of inhibition, poor memory or low attention may suffer from mental health problems as young adults or teenagers.
On a global scale, mental disorders affect about 10% of adolescents and children, with researchers finding that 75% of the disorders diagnosed in adulthood usually begin during adolescence or childhood. For instance, disorders such as psychosis, depression and bipolar disorder often emerge during adolescence and continue into adulthood.
The researchers note in their study, which was reported in “JAMA Network Open,” that targeting certain markers in childhood for early treatment may assist in reducing the risk of the children developing psychopathological issues such as psychosis, depression and borderline personality disorder in their adult lives or during adolescence.
The study explains that cognitive deficits are key features of mental disorders and can help predict long-term prognosis.
For their study, the researchers examined data from a preliminary UK cohort made up of more than 13,000 individuals who had been born April 1991 through December 1992, which led to the discovery of associations between mental health problems in later life and childhood cognitive issues.
For instance, the researchers found that:
- Memory deficits in 10-year-olds were linked to hypomania at ages 22 to 23
- Shortfalls in attention in 8-year-olds paved the way for the development of depression at 17 or 18 years of age as well as borderline personality disorder symptoms at 11 and 12 years
Prior studies have provided evidence proposing a link between symptoms of childhood attention deficit hyperactivity disorder and adult borderline personality disorder, which implies that ADHD may be a risk factor for borderline personality disorder.
Dr. Isabel Morales-Muñoz from the Finnish Institute for Mental Health and the Mental Health Institute at the University of Birmingham stated that the study underlined the potential effect of childhood cognitive deficits on young individual’s mental health, proposing certain links with specific conditions. Morales- Muñoz, who was also the study’s lead author, then added that prevention strategies that centered on reducing these issues could help decrease the risk of the children developing associated mental health issues in early adulthood and during adolescence.
This research also backs the theory that difficulties with inhibition in childhood sets the scene for psychotic disorders like schizophrenia.
Steven Marwaha, Matthew R. Broome, Pavan K. Mallikarjun and Rachel Upthegrove were also members of the research team for this study.
It is of concern that childhood cognitive issues can develop into mental health problems later in life, but the silver lining in this cloud is many companies, including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), are working to revolutionize the way in which mental health conditions are treated, which could bring lasting results to patients.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that licenses Berubicin from CNSP. Berubicin is designed for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). According to the announcement, fast track designation allows the company to interact more frequently with the FDA for the purposes of expediting the development and review process; the designation is reserved for drugs with the potential to address unmet medical need in the treatment of serious or life-threatening conditions. According to WPD, GBM is one of the most aggressive and deadly types of brain cancer, and many patients have almost no meaningful treatment options. The fast track designation creates an accelerated pathway for CNS Pharmaceuticals to gain approval for Berubicin, a move that offers significant potential benefits for WPD because the company has the rights to produce and sell the drug candidate in 29 countries, primarily in Europe. Most recently, CNSP began enrolling patients in its upcoming study of Berubicin.
To view the full press release, visit https://ibn.fm/mPNeO
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer.
Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
A recent study has found that drivers who consume marijuana may not perform or feel impaired. The study found that, instead, drivers who used marijuana would sometimes experience a positive effect on their driving.
This comes at a time when policy makers are working to decide whether driving while under the influence of marijuana warrants similar penalties to driving while under the influence of alcohol in various states across the country. Under the law, impairment is defined as a state of diminished or weakened function.
In many states, the legal limit for blood–alcohol content is 0.08. It is known that a driver who has been awake for more than 20 hours drives with the same impairment level as an individual with the aforementioned blood-alcohol content. However, the stance on marijuana impairment keeps shifting because while it is known that the plant does cause impairment, establishing an acceptable limit seems to be a challenge.
The fact that marijuana metabolites also remain in the human saliva or blood long after the plant’s effects have worn off is also a challenge as it makes it harder for cannabis breathalyzer tests to conclusively measure the impairment level of a driver who’s been using cannabis.
Despite this, some states, including Colorado, have still imposed limits on the level of THC metabolites that can be found in a driver’s blood.
The study, which was conducted by University of Iowa researchers, found that marijuana compounds that give rise to other effects, apart from being high, could probably help individuals drive a bit better. The study, which was reported in the “Traffic Injury Prevention” journal, involved 10 drivers who were each evaluated on their road abilities two hours after they had consumed marijuana.
Each driver was asked to rate their perceived level of impairment before they performed some simulated tasks. Prior research had discovered that drivers who were stoned took fewer risks and were more aware of their impairment when compared to drivers who were inebriated and took more risks.
The authors of the study explained that with regard to longitudinal and lateral control, a growing perception of stimulation gave rise to a positive effect on the drivers’ performance. They added that the study results offered a better understanding of how various strains of marijuana, which gave rise to different experiences for users, could affect driving safety.
The researchers also noted that drug effects that produced more high or stoned feelings resulted in a greater negative impact on driving while those that caused more stimulation had a lesser effect on driving. This isn’t to mean that driving after consuming marijuana is safe, it just means that the level of impairment may not be as pronounced, depending on the marijuana strain consumed.
This study highlights why companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) have invested immensely in studying the specific effects of various cannabinoids so that they can develop therapeutic formulations to treat a variety of conditions.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://cnw.fm/XPHYF
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Cannabis and cannabis extracts are becoming more popular as more states across the country legalize the plant for recreational and/or medical use. CBD, or cannabidiol, is a chemical compound that is extracted from the cannabis sativa plant. The compound can be consumed through edible consumption or smoke inhalation, in addition to being applied topically. It interacts with neuro-receptors in an individual’s endocannabinoid system, which send signals between the body’s cells to help regulate the immune system, homeostasis, mood and movement.
Cannabidiol is usually extracted in oil form and has recently become popular because of its calming effects. Below are a few ways CBD oil can benefit health and wellness, as suggested by preliminary research on the compound.
Protect against neurological ailments
Clinical and preclinical studies have found that CBD possesses anti-inflammatory and antioxidant properties that could offer considerable protection against various pathological disorders. Some preclinical studies also propose that the compound produces beneficial effects against multiple sclerosis, Alzheimer’s disease and Parkinson’ disease.
Alleviate pain
Studies conducted in the United States indicate that CBD is efficacious in treating chronic pain when administered topically. Research results from a 2020 study show that the use of topical CBD in managing pain in patients with symptomatic peripheral neuropathy resulted in considerable reductions in intense sharp pains.
Reduce symptoms of ALS
Amyotrophic lateral sclerosis (“ALS”) is an ailment that causes nerve cells in an individual’s spinal cord and brain to deteriorate, which brings about loss in muscle control. The disease has no cure, and only two medications exist that are approved by the FDA for the management of this condition. A 2019 study suggests that ALS patients can benefit from a combined CBD and THC treatment, with patients who suffered from mild-to-severe muscle stiffness and tightness reporting high levels of satisfaction.
Decrease symptoms of post-traumatic stress disorder
A 2018 study that involved 11 individuals who all suffer from PTSD found that the use of CBD in conjunction with psychiatric care decreased the patients’ symptoms. Other studies on the same topic have found that CBD used together with THC enhances the former’s effects in reducing symptoms of PTSD.
Neutralize anxiety
Numerous studies on the use of cannabis and its extracts in helping combat anxiety have been conducted in the recent past. A study conducted in 2017 found that CBD was effective in reducing anxiety when used in moderate doses.
The above are only a few of the ways in which CBD can be provide health benefits. Researchers are focused on finding out more about this compound and any additional benefits that it may possess.
Many companies such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are marketing a variety of CBD-infused products. It is good to learn that scientific studies are revealing some of the benefits that consumers could derive from using these widely available products.
NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Kaival Brands (OTCQB: KAVL), a company focused on growing and incubating innovative and profitable products into mature and dominant brands, today announced that e-cigarette and nicotine-pouch maker Bidi Vapor LLC has scheduled its executives and sales teams to attend several live, in-person conferences and trade shows as COVID-19 vaccination numbers rise across the country. Among these events are Winsight and CSP magazine’s Outlook Leadership conference, ASD Market Week for wholesale and retail buyers, as well as the NACS Show for convenience-store retailers and distributors. “As COVID-19 restrictions loosen, Bidi Vapor and Kaival Brands are happy to return to a more face-to-face form of marketing,” said Niraj Patel, president and CEO of Kaival Brands. “This approach builds trust when we can explain to people in person the benefits of a high-quality, premium e-cigarette.”
To view the full press release, visit https://ibn.fm/78dWj
About Kaival Brands Innovations Group Inc.
Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own, or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products currently manufactured by Bidi Vapor LLC. For more information about the company, visit www.KaivalBrands.com.
NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- SMEs account for about 60% of China’s production GDP
- However, they have a relatively low adoption of SaaS and automation tools
- Infobird, through innovation and education, is trying to rectify this issue
- By targeting these SMEs, it will be impacting the entire Chinese SaaS market, positioning it as a global leader
As of 2019, the Chinese software-as-a-service SaaS market was estimated between $3.7 billion and $6 billion in value (https://ibn.fm/NBymg). That was just 6% less than the total value of the global SaaS market. This is great for the country. However, when compared to other nations such as the United States, the United Kingdom, Germany, Japan, South Korea, and India, it could use a little more adoption of SaaS and enjoy the benefits and growth that come with it.
Infobird (NASDAQ: IFDB) seeks to address that, mainly through innovation and a marketing strategy meant to grow its market share and the SaaS industry in China.
Infobird has constantly been pushing the envelope regarding the development and launch of the next generation SaaS in China. By targeting leading industries and specific enterprises within these industries, the company is slowly but surely proving what it can do and its potential for taking over both the Chinese and the global markets (https://ibn.fm/qqhHQ).
Currently, small and medium-sized enterprises (“SMEs”) account for about 60% of China’s production GDP. However, their rate of adoption of automation and SaaS is relatively low. This sector’s potential for adopting SaaS far exceeds most markets worldwide, including but not limited to the United States, India, Japan, Germany, and the United Kingdom. Despite its potential, this market is relatively untapped, and Infobird is pushing to fix the situation, firstly educating these organizations and the entrepreneurs therein on the benefits of SaaS, and innovating to suit their needs and wants.
Infobird is a SaaS provider focusing on artificial intelligence (“AI”)-powered customer engagement solutions for the Chinese market. Its tech infrastructure is founded on cloud computing, machine learning, patented Voice over Internet Protocol (“VoIP”) application technologies, and AI (https://ibn.fm/EylhH).
Since its inception back in October 2001, the company has stayed committed to empowering clients with solutions specifically designed for the issues they face, all while increasing their revenue, reducing costs, enhancing service quality, and overall customer satisfaction. With its focus on SMEs, Infobird is trying to grow China into a leading SaaS market globally. By constantly innovating and tailoring its products and services to the customers, the company is slowly demystifying software and automation in business processes.
With its flagship customer engagement software, Infobird can show customers the value of AI customer engagement, along with AI salesforce management. The product, which over 358 customers currently use in industries including health care, education, consumer products, public services, and finance, is proving valuable and essential to improving customer satisfaction and the overall efficiency of an organization’s operations. As such, Infobird is slowly showing its consumers in the Chinese market the value of leveraging its tools and the benefits that come with it.
As it currently stands, Infobird’s role is far bigger than the company itself. Through its efforts to innovate and push its products in the market, it is aiding in growing SaaS adoption within China. More importantly, it allows China to grow and achieve its potential to become a global leader in the SaaS market.
For more information, visit the company’s website at www.Infobird.com/en/index.html.
NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer
ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
Ideanomics (NASDAQ: IDEX) recently completed the acquisition of 100% of privately held US Hybrid, heralding entry into the burgeoning EV powertrain market that is expected to grow at a 16% CAGR between 2020 and 2027. US Hybrid manufactures and sells electric powertrain components and fuel cell engines for medium and heavy-duty municipality vehicles, commercial trucks, buses, and specialty cars. The company welcomes US Hybrid CEO Dr. Abas Goodarzi, Ph.D., PE, and his entire team, with the acquisition expected to bring synergistic benefits to the various companies under the Ideanomics Mobility umbrella. A recent article quoted Dr. Goodarzi as saying: “Ideanomics has emerged as a true powerhouse in the commercial EV sector with a synergistic ecosystem of technologies and solutions that covers the entire value chain of electrification. We look forward to leveraging that strength going forward.”
To view the full article, visit https://ibn.fm/AXvMI
About Ideanomics Inc.
Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under an innovative sales-to financing-to-charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and shareholders with the opportunity to participate in high-potential growth industries. For more information, visit www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th – 15th, 2021
RALEIGH, NC / July 8, 2021 / Access to Giving – an investor conference themed around investor education and advocacy begins next week, July 13th – 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1×1 meetings with qualified investors throughout the event.
John Hope Bryant, guest host on CNBC and CEO of Operation HOPE will deliver the keynote to kick off the conference on Tuesday, July 13th at 9 am ET. Three educational panels will also take place over the three days at 11 am each day. The panels are as follows:
Tuesday, July 13th, 2021
Panel: ESG
Speakers: Andy Behar, CEO, As You Sow and Dr. Christine Chow, IHS Markit
Wednesday, July 14th, 2021
Panel: Pledge 1% – How Companies & VCs/Investors Can Leverage Equity for Social Impact
Speakers: Jan D’Alesandro, Tim Connors and Jessica Lindl
Thursday, July 15th, 2021
Panel: Human Capital
Speakers: Starla Sampaco, Nihad Karabernou McBride and Georgia Homsany
A live webcast, including audio, video, and presentation slides, will be accessible for registered participants here. Interested parties unable to watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available here as well following the conclusion of the event.
Join us and gain an understanding and potential trends and key value drivers across a wide array of industries. If you are a qualified investor, register here and pledge to take meetings. If you’re new to the investment world, come listen to some presentations, panels, and learn more.
The full agenda can be found here, and the full event website can be found here.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email Angie Goertz or call 919-228-6240.
Companies registered to date:
| Organization |
Ticker |
Website |
| Acer Therapeutics |
ACER |
http://www.acertx.com |
| Addex Therapeutics Ltd. |
ADXN |
https://www.addextherapeutics.com/en/ |
| Agile Therapeutics, Inc. |
AGRX |
https://agiletherapeutics.com/ |
| Alpha Cognition |
ACOG |
https://www.alphacognition.com/ |
| Altigen Communications |
ATGN |
https://www.altigen.com/ |
| ARCA biopharma, Inc. |
ABIO |
https://arcabio.com/ |
| Auddia Inc. |
AUUD |
https://auddia.com/ |
| AYRO Inc |
AYRO |
http://www.ayro.com |
| Basanite Industries |
BASA |
https://www.basaniteindustries.com/ |
| Biomerica |
BMRA |
https://www.biomerica.com/ |
| BK Technologies |
BKTI |
http://www.bktechnologies.com |
| Blessed Bites |
PRIVATE |
https://www.theblessedbites.com/ |
| Blue Star Foods |
BSFC |
https://www.bluestarfoods.com/ |
| BriaCell Therapeutics Co |
BCTX |
https://briacell.com/ |
| Brooklyn Immunotherapeutics |
BTX |
https://www.brooklynitx.com/ |
| Data Storage Corporation |
DTST |
https://www.datastoragecorp.com/ |
| Delcath Systems Inc. |
DCTH |
http://delcath.com |
| Diamcor Mining Inc. |
DMIFF |
http://www.diamcormining.com/ |
| Dolphin Entertainment Inc. |
DLPN |
https://www.dolphinentertainment.com |
| Flux Power Holdings |
FLUX |
http://www.fluxpower.com |
| Greenbrook TMS NeuroHealth Centers |
GBNH |
https://www.greenbrooktms.com/ |
| HAVN Life Sciences Inc. (HAVLF) |
HAVLF |
https://havnlife.com/ |
| Hollywall Entertainment |
HWAL |
https://hollywall.com/ |
| Issuer Direct Corporation |
ISDR |
https://www.issuerdirect.com |
| Issuer Pixel |
PRIVATE |
https://issuerpixel.com/ |
| Item 9 Labs Corp. (INLB) |
INLB |
https://www.item9labscorp.com/ |
| Know Labs, Inc. (KNWN) |
KNWN |
https://www.knowlabs.co/ |
| LexaGene |
LXXGF |
https://lexagene.com/ |
| Mechanical Technology, Incorporated |
MKTY |
https://www.mechtech.com/ |
| Metamaterial, Inc. |
MMATF |
https://metamaterial.com/ |
| Miravo Healthcare |
MRVFF |
https://www.miravohealthcare.com/ |
| Nemaura Medical |
NMRD |
https://nemauramedical.com/ |
| Nephros, Inc. |
NEPH |
https://www.nephros.com/ |
| NeuroOne Medical Technologies Corp. |
NMTC |
https://n1mtc.com/ |
| NLS Pharmaceuticals |
NLSP |
https://nlspharma.com/ |
| Oblong Inc. |
OBLG |
https://www.oblong.com/ |
| Panbela Therapeutics, Inc. |
PBLA |
https://panbela.com/ |
| Petros Pharmaceuticals |
PTPI |
https://www.petrospharma.com/ |
| POSaBIT Systems Corporation |
POSAF |
https://www.posabit.com/ |
| Processa Pharmaceuticals, Inc. |
PCSA |
https://processapharmaceuticals.com/ |
| ProPhase Labs, Inc. |
PRPH |
https://www.prophaselabs.com/ |
| Protagenic Therapeutics, Inc. |
PTIX |
https://protagenic.com/ |
| Quality Online Education Group Inc. |
QOEG |
http://qualityonline.education |
| Quipt Home Medical |
QIPT |
https://www.protechhomemedical.com/ |
| Soligenix, Inc. |
SNGX |
http://www.soligenix.com |
| Star Equity Holdings |
STRR |
https://www.starequity.com/home |
| Tego Cyber Inc. |
TGCB |
https://tegocyber.com |
| Thunderbird Entertainment |
THBRF |
http://thunderbird.tv/ |
| TraQiQ Inc. |
TRIQ |
https://www.traqiq.com/ |
| Uncommon Giving Corporation |
PRIVATE |
https://uncommon.today/ |
| Verb Technology Company |
VERB |
http://www.verb.tech |
| Wellteq |
WTEQ |
https://wellteq.co/ |
| Windtree Therapeutics, Inc. |
WINT |
http://www.windtreetx.com |
About Access to Giving
Access to Giving is the first-of-its-kind virtual investor conference and will be held July 13th – 15th, 2021. Companies will have the opportunity to tell their story and conduct 1×1’s with qualified investors for charity. 100% of monies raised through donations for 1×1 meetings will be given to causes that are focused on financial literacy and financial education.
About Issuer Direct Corporation
Issuer Direct® is an industry-leading communications and compliance company focusing on the needs of corporate issuers. Issuer Direct’s principal platform, Platform id. ™, empowers users by thoughtfully integrating the most relevant tools, technologies, and services, thus eliminating the complexity associated with producing and distributing financial and business communications. Headquartered in Raleigh, NC, Issuer Direct serves thousands of public and private companies globally. For more information, please visit www.issuerdirect.com.
Contact Information:
Angie Goertz, Vice President of Events
Issuer Direct Corporation
Office: (919) 228-6240
Email: Angie.Goertz@IssuerDirect.com
Oil prices are almost 40% higher than they began the year. Should the 5% dip over the past week be cause for concern among energy investors? Perhaps the reasons for the dip, impact on competition, and the U.S. production level ought to attract the most focus.
The volatility comes after an aborted meeting of OPEC+, the outcome of which was expected to result in an agreement to increase output, undoing 2020 cuts implemented as the economic lockdowns caused a worldwide glut of crude oil. Instead, OPEC+, which includes the original OPEC cartel members and their oil-producing allies, failed to reach an agreement.
Background:
In 2020 OPEC+ made the decision to severely slow production by nearly 10 million barrels a day as demand vanished from the impact of lockdown orders in economies both large and small. In 2021, the price of oil had risen as much as 50% to its high point as the world began relaxing COVID-era restrictions. Oil-exporting nations are now looking to orchestrate the way forward out of the pandemic crisis and into a world where world energy needs are expected to turn sharply away from petroleum.
The Agreement that Didn’t Happen
The expected agreement that would have increased world oil production fell apart because of a conflict between Saudi Arabia and the U.A.E. The U.A.E. asked to have its production target increased, this would have expanded its percentage of combined OPEC output. Increasing one country’s overall share has a tendency to create conflict. The cartel has stayed united with minimum open conflict, and they only act with a unanimous vote. The current outcome of “status quo” where the countries are expected to operate under the existing Covid era limited output will have the effect of keeping oil prices high but perhaps cut into potential revenue for the members involved.
U.S. Oil Prices vs. International
U.S. oil prices jumped and then declined yesterday (July 7) as traders deciphered and adjusted to the new OPEC outlook. Oil price volatility isn’t all that the markets experienced by the uncertain future. Oil spreads, the gap between international crude and U.S. production have narrowed. Producers globally benefit from higher prices. Downstream related business such as refiners prefer fat spreads between U.S. and non-domestic per barrel prices. The narrowing can be seen as a drag on some U.S. energy stocks.
Benchmark U.S. crude oil prices were up about 1% Wednesday morning (July 7), then turned sharply down about 2.6% by 10:40 a.m. E.S.T. Benchmark global crude prices began up about 0.8% before turning lower, dropping about 2.1%. West Texas Intermediate oil futures, the U.S. benchmark, are at $71.48 a barrel. Brent crude oil futures, the international benchmark, are at $72.95 a barrel.
Supply-demand factors in the U.S. are a driver of the spread compression. U.S. inventory post-Covid is at a massive deficit compared to normal levels. As the U.S. economy is sprinting out of last year’s poor economy, the rest of the world is crawling forward from the problems. Narrower spreads tend to reduce U.S. exports and invite imports. This dampens the potential for U.S. producers.
OPEC controls about one-third of global oil production. A rift between two rival countries could impact what occurs with energy sources that compete with oil and even help speed or slow movement away from petroleum. Competition between Gulf allies is heating up in other areas as well as the countries are working to diversify their revenue to be less reliant on oil as the move to reduce dependence accelerates. Increasing Petrodollars ($ U.S. dollars exchanged for crude) are important.
Take-Away
The rift between Saudi Arabia and the U.A.E. may widen or narrow. The countries are going through a challenging time where revising their economies for diversified income appears critical. The U.A.E. is ahead of the Saudis on this; financing additional economic revitalization projects increases the thirst for maximizing oil sales profit.
What occurs halfway across the world impacts the spread between U.S. crude and all other sources. When the spread narrows, other sources become more attractive than they had been. This can impact not just domestic oil sales but related businesses down the line, and even competing energy sources.
Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations and research activities with various academic and clinical research organizations, including the transfer of its intellectual property assets to its recently formed wholly-owned Ireland subsidiary.
The Company continues its progression of scaling and building upon its IP portfolio of novel psychedelic compounds, delivery platforms and methods of use in psychiatric indications.
Since inception, the Company has been able to progress the following initiatives all of which are accelerated from its growing portfolio of intellectual property:
- expanded IP portfolio to 12 patent filings;
- filed an international patent application (PCT) that brings the potential to obtain patent coverage in 153 countries;
- grown discovery pipeline of psychedelic molecules to 50+;
- progressed with 4 active drug programs utilizing its Novel Psychedelic Compounds of which 3 mental health indications have been selected: Major Depressive Disorder, Alcohol Use Disorder and Anxiety Disorders (General Anxiety Disorder / Social Anxiety Disorder); and
- completed 51 pre-clinical studies to support progression of novel molecules into clinical studies in early 2022
About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company scaling and building upon its IP portfolio, progression in relation to the Company’s four active drug programs, and the potential for the Company to obtain patent coverage in 153 countries. There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.
The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005953/en/
Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Contacts :
John Kanakis
Cybin Inc.
John@cybin.com
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. “Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the areas impacted,” reads a recent article. “BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected. Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market.”
To view the full article, visit: https://ibn.fm/feZf8
About Brain Scientific Inc.
Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The majority of individuals who contract the coronavirus suffer from the symptoms of coughing, fever and difficulty breathing before recovering in about two weeks. However, some individuals suffer persistent symptoms, informally referred to as long COVID. Researchers estimate that these individuals make up 10% to 30% of the population.
While researchers have been unable to find a definitive cause as to why some people suffer from long-term symptoms, they have proposed a few theories as well as growing information about the disease.
So, what can we deduce from long COVID?
Working definitions from researchers show that the term “long COVID” describes a situation where individuals experience persistent symptoms after contracting the coronavirus. The most common symptoms observed in sufferers of long COVID are sleep disturbance, muscle aches, brain fog, headaches, heart palpitations, chest pain, shortness of breath and fatigue. However, researchers note that individuals may also experience symptoms such as an inability to interact with and work in society, depression, and loss of taste and smell.
Researchers aren’t sure what causes long COVID but theorize that an individual’s immune system may misfire when they’re infected. This is supported by the improvements observed in the symptoms of patients who suffer from long COVID after they’ve received the coronavirus vaccine. The researchers note that no final conclusions have been made and that it is challenging to determine the proportion of individuals who contract the coronavirus and end up with persistent symptoms.
However, a current study focused on coronavirus immunity is being conducted by the Walter and Eliza Hall Institute. That study has discovered that more than 30% of the participants are still experiencing symptoms of long COVID some 40 weeks after diagnosis. It should be noted that the study isn’t community based and was not developed to measure how common long COVID was in the wider population.
Additionally, data emerging from other sources cites different rates, with another study conducted in the UK finding a 30% rate and a separate study by the WHO noting that the rate is 10%. Researchers note that the proportion of individuals who are affected by the disease may also vary between different countries.
As there are no definitive clinical tests to determine whether an individual has the disease, treating it can be challenging. Clinicians observe that individuals suffering from mild symptoms may not need treatment, but information and validation may be useful. However, those suffering from persistent symptoms should seek clinical care, as it is essential that these severe symptoms get acknowledged so that they can be treated by a multidisciplinary medical team and allow patients to receive valuable support and assistance.
As superior Covid-19 diagnostics are brought to market by companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a time may come when long Covid is better understood by the medical community.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD)
Management to host corporate update conference call and audio webcast today at 2:00 p.m. PT
SOUTH SAN FRANCISCO, Calif., June 29, 2021 — VistaGen Therapeutics , Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year ended March 31, 2021.
“Our fiscal year 2021 was transformative, involving several drug development, financial and regulatory milestones that fortified the foundation for our very strong start this fiscal year. Notably, we achieved an important consensus with the U.S. Food and Drug Administration regarding our PALISADE Phase 3 program for PH94B in social anxiety disorder. Building on that positive meeting, we completed a PH94B collaboration in ex-U.S. markets, strengthened our balance sheet with substantial investment from numerous long-biased, healthcare-focused institutional investors, and advanced several development programs across our CNS pipeline, most notably preparations for PALISADE-1, our U.S. multi-center Phase 3 clinical study of PH94B as a potential rapid-onset, acute treatment of anxiety in adults with social anxiety disorder. If successful, PALISADE-1 is designed to be among the studies necessary to support a potential PH94B New Drug Application to the U.S. Food and Drug Administration in 2023. We recently initiated PALISADE-1, moving us closer to our goal of going beyond the current treatment paradigm for social anxiety disorder, not only displacing antidepressants, benzodiazepines and beta blockers, but also reaching those in need of support who find those therapies to be undesirable or inadequate. We anticipate topline data from PALISADE-1 in mid-2022. Later this year, we expect to launch PALISADE-2, a second U.S. multi-center Phase 3 clinical study of PH94B designed to be substantially similar to PALISADE-1 and equally supportive of our U.S. New Drug Application goal.”
Singh added, “During the current fiscal year, we also expect to prepare for and initiate several exploratory Phase 2A clinical trials of PH94B in additional anxiety disorders, advance preparations necessary to initiate a U.S. multi-center Phase 2B clinical trial of PH10 as a potential rapid-onset, stand-alone treatment for major depressive disorder, and initiate a Phase 1B clinical trial of AV-101 with probenecid, which, if successful, has the potential to support exploratory Phase 2A development of the combination in several CNS disorders.”
“To develop and commercialize game-changing treatments, you need great people. During the past year, we have strengthened our team by adding several key personnel with deep CNS drug development and commercial experience to drive our programs through important late-stage development milestones and appropriately-timed pre-commercial and commercial launch operations. We look forward to initiating several more clinical trials this fiscal year and remain focused on pursuing our mission to improve mental health and well-being for individuals in the U.S. and abroad,” concluded Singh.
Corporate Highlights
- Reached consensus with U.S. Food and Drug Administration (FDA) on key aspects of the design of Phase 3 clinical trials of PH94B for acute treatment of anxiety in adults with SAD after a positive meeting. The Phase 3 clinical studies of PH94B in the Company’s PALISADE Phase 3 program will substantially mirror the public speaking challenge in the statistically significant Phase 2 study of PH94B, providing significant time and cost-efficiency for the program.
- Entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, Inc. (now AffaMed Therapeutics, Inc.) for clinical development and commercialization of PH94B in Greater China, South Korea and Southeast Asia (Territory), pursuant to which VistaGen received a non-dilutive upfront payment of $5 million. VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million and tiered royalties on sales of PH94B in the Territory, if Phase 3 development efforts there are successful.
- Reported positive preclinical data differentiating the mechanism of action (MOA) of PH94B and PH10 from risk-ridden benzodiazepines, demonstrating that the MOA of PH94B and PH10 does not involve direct activation of GABA-A receptors, in distinct contrast to the MOA of benzodiazepines, which act as direct positive modulators of GABA-A receptors.
- Reported positive preclinical data demonstrating the potential of the combination of AV-101 and probenecid to substantially increase the brain concentration of AV-101’s active metabolite, 7-Cl-KYN, a potent and selective full antagonist of the NMDA receptor glycine co-agonist site, thereby reducing, rather than blocking, NMDA receptor signaling.
- Raised $127.5 million gross proceeds from partnering and corporate finance transactions, including a $100 million underwritten public offering led by Jefferies Group LLC and William Blair & Company involving significant participation from key healthcare-focused institutional investors, such as Acuta Capital, New Enterprise Associates, OrbiMed and Venrock Healthcare Capital Partners.
- Appointed key senior leadership to execute corporate initiatives through commercialization.
CNS Pipeline Updates
PH94B
PH94B is a synthetic investigational neurosteroid developed from proprietary compounds called pherines. With its novel MOA, PH94B is an odorless nasal spray administered at microgram-level doses to achieve rapid-onset anti-anxiety, or anxiolytic, effects. The novel pharmacological MOA of PH94B is fundamentally differentiated from that of all FDA-approved anti-anxiety drugs, including all antidepressants approved by the FDA for treatment of SAD, as well as all benzodiazepines and beta blockers prescribed on an off-label basis. PH94B engages peripheral chemosensory receptors in nasal passages that trigger a subset of neurons in the main olfactory bulbs (OB) at the base of the brain. The OB neurons then stimulate inhibitory GABAergic neurons in the limbic amygdala, decreasing the activity of the sympathetic nervous system, and facilitating fear extinction activity of the limbic-hypothalamic system, the main fear and anxiety center in the brain, as well as in other parts of the brain. Importantly, PH94B does not require systemic uptake and distribution to produce its rapid-onset anti-anxiety effects.
VistaGen recently initiated its PALISADE Phase 3 program with PALISADE-1, a U.S., multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical study to evaluate the efficacy and safety of PH94B for the acute treatment of anxiety in adults with SAD. The Company expects to initiate PALISADE-2, the second U.S. Phase 3 study in its PALISADE Phase 3 program, in the second half of 2021. If successful, these clinical studies are designed to be among the studies necessary to support a potential U.S. New Drug Application (NDA) to the FDA. PH94B has been granted Fast Track designation status by the FDA for development as an acute treatment of anxiety in adults with SAD.
In addition to SAD, the Company is also preparing for exploratory Phase 2A clinical studies of PH94B in adults experiencing other anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, and pre-procedural anxiety.
PH10
PH10 is a synthetic investigational neurosteroid, which also was developed from proprietary compounds called pherines. Its novel, rapid-onset MOA is fundamentally differentiated from the MOA of all current treatments for major depressive disorder (MDD) and other depression disorders. PH10 is self-administered at microgram-level doses as an odorless nasal spray. PH10 activates nasal chemosensory cells in the nasal passages, connected to neural circuits in the brain that produce antidepressant effects. Specifically, PH10 engages peripheral chemosensory receptors in the nasal passages that trigger a subset of neurons in the main OB that stimulate neurons in the limbic amygdala. This is turn increases activity of the limbic-hypothalamic sympathetic nervous system and increases the release of catecholamines. Importantly, unlike all currently approved oral antidepressants, PH10 does not require systemic uptake and distribution to produce rapid-onset of antidepressant effects. In all clinical studies to date, PH10 has not caused psychological side effects (such as dissociation and hallucinations) or safety concerns that may be associated with rapid-onset ketamine-based therapy, including intravenous ketamine or intranasal ketamine.
Exploratory Phase 2A clinical development of PH10 for MDD has been completed. VistaGen is now preparing for Phase 2B clinical development of PH10. The Company expects to initiate a U.S. multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PH10 as a potential stand-alone treatment for MDD in mid-2022. PH10 also has potential as a novel treatment for treatment-resistant depression, postpartum depression and suicidal ideation.
AV-101
AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA) and targets the N-methyl-D-aspartate receptor (NMDAR), an ionotropic glutamate receptor in the brain. Abnormal NMDAR function is associated with numerous CNS diseases and disorders. AV-101 is a potent and selective full antagonist of the glycine co-agonist site of the NMDAR that inhibits the function of the NMDAR. However, unlike ketamine and many other NMDAR antagonists, 7-Cl-KYNA is not an ion channel blocker. At doses administered in all studies to date, AV-101 has been observed to be orally bioavailable, well tolerated and has not exhibited dissociative or hallucinogenic psychological side effects or safety concerns. In light of these findings and data from preclinical studies, the Company believes that AV-101, in combination with FDA-approved probenecid, has potential to become a new oral treatment alternative for MDD and certain neurological indications involving the NMDAR.
VistaGen is currently preparing for a Phase 1B clinical study to evaluate AV-101 in combination with probenecid. The Company expects to initiate the study in the second half of 2021. The FDA has granted Fast Track designation for development of AV-101 as a potential adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain. AV-101 also has the potential to be developed as a treatment for levodopa-induced dyskinesia, suicidal ideation, and epilepsy.
Key senior leadership additions
VistaGen strengthened its leadership by adding key personnel with extensive CNS drug development and commercial experience to drive its clinical and commercial programs through important late-stage clinical development milestones and potential commercial launch and beyond. The Company recently added key team members in multiple areas such as clinical operations, research and development, CMC, regulatory affairs and commercial operations. Notably, the addition of Ann Cunningham as the Company’s Chief Commercial Officer has advanced pre-commercial planning for PH94B in SAD, as well as for a broad range of other anxiety and depression markets. The Company also added pharmaceutical industry veteran Dr. Joanne Curley to its Board of Directors. Dr. Curley has deep experience in pharmaceutical product development, operations, and commercialization.
Fiscal Year 2021 Financial Results
Revenue: The Company recognized $1.1 million in sublicense revenue from its $5 million non-dilutive upfront payment pursuant to its PH94B development and commercialization agreement with EverInsight Therapeutics (now AffaMed Therapeutics) during the year ended March 31, 2021, compared to none in the year ended March 31, 2020.
Research and development (R&D) expense: Research and development expense decreased from $13.4 million to $12.5 million for the years ended March 31, 2020 and 2021, respectively. The decrease is primarily due to the completion of a Phase 2 clinical study of AV-101 in MDD in Fiscal 2020, offset by increased development expenses for PH94B and PH10 in Fiscal 2021.
General and administrative (G&A) expense: General and administrative expense decreased to approximately $6.5 million from approximately $7.4 million for the years ended March 31, 2021 and 2020, respectively. Cash compensation expense for the year ended March 31, 2021 increased by approximately $0.7 million, including the impact of new employees, and was offset by a decrease of approximately $1.0 million in noncash stock-based compensation for the year ended March 31, 2021 compared to those expenses in the year ended March 31, 2020. Further, in the year ended March 31, 2020, the Company modified certain outstanding warrants and recognized non-cash warrant modification expense of approximately $0.8 million.
Net loss: Net loss for the fiscal years ended March 31, 2021 and 2020 was approximately $17.9 million and $20.8 million, respectively.
Cash Position: At March 31, 2021, the Company had cash and cash equivalents of approximately $103.1 million.
As of June 29, 2021, the Company had 191,382,350 shares of common stock outstanding.
Conference Call
VistaGen will host a conference call and live audio webcast this afternoon at 2:00 p.m. Pacific Time to provide a corporate update and discuss its financial results for its fiscal year ended March 31, 2021.
U.S. Dial-in (Toll Free): 1-877-407-9716
International Dial-in Number (Toll): 1-201-493-6779
Conference ID: 13720908
Webcast Link: http://public.viavid.com/index.php?id=145419
A telephone playback of the conference call will be available after approximately 5:00 p.m. Pacific Time on June 29, 2020. To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay PIN number 13720908.
About VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS indications. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter , LinkedIn , and Facebook .
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Our actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties relating to delays in launching and/or conducting our planned clinical trials, including delays due to the impact of the COVID-19 pandemic; fluctuating costs of materials and other resources required to conduct our planned clinical and non-clinical trials; market conditions; the impact of general economic, industry or political conditions in the United States or internationally; adverse healthcare reforms and changes of laws and regulations; manufacturing and marketing risks, which may include, but are not limited to, unavailability of or delays in delivery of raw materials for manufacture of our CNS drug candidates and difficulty in initiating or conducting clinical trials; inadequate and/or untimely supply of one or more of our CNS drug candidates to meet demand; entry of competitive products; and other technical and unexpected hurdles in the development, manufacture and commercialization of our CNS drug candidates; and the risks more fully discussed in the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2021, filed earlier today, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). Our SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, other than as may be required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.
VistaGen Company Contacts
Mark McPartland and Mark Flather
VistaGen Therapeutics
Phone: (650) 577-3606; (650) 577-3617
Email: IR@vistagen.com
|
|
| VISTAGEN THERAPEUTICS, INC. |
| CONSOLIDATED BALANCE SHEETS |
| (Amounts in dollars, except share amounts) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
March 31, |
|
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ASSETS |
| Current assets: |
|
|
|
|
|
| Cash and cash equivalents |
|
|
$ |
103,108,300 |
|
|
$ |
1,355,100 |
|
| Receivable from collaboration partner |
|
|
|
40,600 |
|
|
|
– |
|
| Prepaid expenses and other current assets |
|
|
|
835,100 |
|
|
|
225,100 |
|
| Deferred contract acquisition costs – current portion |
|
|
|
133,500 |
|
|
|
– |
|
| Total current assets |
|
|
|
104,117,500 |
|
|
|
1,580,200 |
|
| Property and equipment, net |
|
|
|
367,400 |
|
|
|
209,600 |
|
| Right of use asset – operating lease |
|
|
|
3,219,600 |
|
|
|
3,579,600 |
|
| Deferred offering costs |
|
|
|
294,900 |
|
|
|
355,100 |
|
| Deferred contract acquisition costs – non-current portion |
|
|
|
234,100 |
|
|
|
– |
|
| Security deposits and other assets |
|
|
|
47,800 |
|
|
|
47,800 |
|
| Total assets |
|
|
$ |
108,281,300 |
|
|
$ |
5,772,300 |
|
|
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
| Current liabilities: |
|
|
|
|
|
| Accounts payable |
|
|
$ |
838,300 |
|
|
$ |
1,836,600 |
|
| Accrued expenses |
|
|
|
1,562,700 |
|
|
|
561,500 |
|
| Current notes payable |
|
|
|
– |
|
|
|
56,500 |
|
| Deferred revenue – current portion |
|
|
|
1,420,200 |
|
|
|
– |
|
| Operating lease obligation – current portion |
|
|
|
364,800 |
|
|
|
313,400 |
|
| Financing lease obligation – current portion |
|
|
|
3,000 |
|
|
|
3,300 |
|
| Total current liabilities |
|
|
|
4,189,000 |
|
|
|
2,771,300 |
|
|
|
|
|
|
|
| Non-current liabilities: |
|
|
|
|
|
| Accrued dividends on Series B Preferred Stock |
|
|
|
6,272,700 |
|
|
|
5,011,800 |
|
| Deferred revenue – non-current portion |
|
|
|
2,490,300 |
|
|
|
– |
|
| Operating lease obligation – non-current portion |
|
|
|
3,350,800 |
|
|
|
3,715,600 |
|
| Financing lease obligation – non-current portion |
|
|
|
– |
|
|
|
3,000 |
|
| Total non-current liabilities |
|
|
|
12,113,800 |
|
|
|
8,730,400 |
|
| Total liabilities |
|
|
|
16,302,800 |
|
|
|
11,501,700 |
|
|
|
|
|
|
|
| Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ equity (deficit): |
|
|
|
|
|
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2021 and 2020: |
|
|
|
|
|
| Series A Preferred, 500,000 shares authorized, issued and outstanding at March 31, 2021 and 2020 |
|
|
|
500 |
|
|
|
500 |
|
| Series B Preferred; 4,000,000 shares authorized at March 31, 2021 and 2020; 1,131,669 shares |
|
|
|
|
|
| and 1,160,240 shares issued and outstanding at March 31, 2021 and 2020, respectively |
|
|
|
1,100 |
|
|
|
1,200 |
|
| Series C Preferred; 3,000,000 shares authorized at March 31, 2021 and 2020; 2,318,012 shares |
|
|
|
|
|
| issued and outstanding at March 31, 2021 and 2020 |
|
|
|
2,300 |
|
|
|
2,300 |
|
| Series D Preferred; 2,000,000 shares and no shares authorized at March 31, 2021 and 2020, respectively; |
|
|
|
|
|
| 402,149 shares and no shares issued and outstanding at March 31, 2021 and March 31, 2020, respectively |
|
|
|
400 |
|
|
|
– |
|
| Common stock, $0.001 par value; 325,000,000 shares and 175,000,000 shares authorized at March 31, 2021 and 2020, |
|
|
|
|
|
| respectively; 180,751,234 and 49,348,707 shares issued at March 31, 2021 and 2020, respectively |
|
|
|
180,800 |
|
|
|
49,300 |
|
| Additional paid-in capital |
|
|
|
315,603,100 |
|
|
|
200,092,800 |
|
| Treasury stock, at cost, 135,665 shares of common stock held at March 31, 2021 and 2020 |
|
|
|
(3,968,100 |
) |
|
|
(3,968,100 |
) |
| Accumulated deficit |
|
|
|
(219,841,600 |
) |
|
|
(201,907,400 |
) |
| Total stockholders’ equity (deficit) |
|
|
|
91,978,500 |
|
|
|
(5,729,400 |
) |
| Total liabilities and stockholders’ equity (deficit) |
|
|
$ |
108,281,300 |
|
|
$ |
5,772,300 |
|
|
|
|
|
|
|
| VISTAGEN THERAPEUTICS |
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
| (Amounts in Dollars, except share amounts) |
|
|
|
|
|
|
|
|
Fiscal Years Ended March 31, |
|
|
|
2021 |
|
|
|
2020 |
|
| Sublicense revenue |
|
$ |
1,089,500 |
|
|
$ |
– |
|
| Total revenues |
|
|
1,089,500 |
|
|
|
– |
|
| Operating expenses: |
|
|
|
|
| Research and development |
|
|
12,476,400 |
|
|
|
13,374,200 |
|
| General and administrative |
|
|
6,546,900 |
|
|
|
7,427,300 |
|
| Total operating expenses |
|
|
19,023,300 |
|
|
|
20,801,500 |
|
| Loss from operations |
|
|
(17,933,800 |
) |
|
|
(20,801,500 |
) |
| Other income and expenses, net: |
|
|
|
|
| Interest income, net |
|
|
1,600 |
|
|
|
30,100 |
|
| Other income |
|
|
600 |
|
|
|
– |
|
| Loss before income taxes |
|
|
(17,931,600 |
) |
|
|
(20,771,400 |
) |
| Income taxes |
|
|
(2,600 |
) |
|
|
(2,600 |
) |
| Net loss and comprehensive loss |
|
$ |
(17,934,200 |
) |
|
$ |
(20,774,000 |
) |
|
|
|
|
|
| Accrued dividends on Series B Preferred stock |
|
|
(1,385,600 |
) |
|
|
(1,263,600 |
) |
| Beneficial conversion feature on Series D |
|
|
|
|
| Preferred stock |
|
|
(23,000,000 |
) |
|
|
– |
|
|
|
|
|
|
| Net loss attributable to common stockholders |
|
$ |
(42,319,800 |
) |
|
$ |
(22,037,600 |
) |
|
|
|
|
|
| Basic and diluted net loss attributable to common |
|
|
|
|
| stockholders per common share |
|
$ |
(0.49 |
) |
|
$ |
(0.50 |
) |
|
|
|
|
|
| Weighted average shares used in computing |
|
|
|
|
| basic and diluted net loss attributable to common |
|
|
|
|
| stockholders per common share |
|
|
86,133,644 |
|
|
|
43,869,523 |
|
|
|
|
|
|
News Provided by GlobeNewswire via QuoteMedia
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) achieved $41.1 million in revenue for fiscal year 2020, representing a 28% year-over-year increase as reflected in its most recent financial report. Now the largest independent alkaline water company in the nation, the company’s accomplishment to lead the pack is impressive and positions it well as the market is projected to reach $1 billion in 2022 (https://cnw.fm/oXjm6). “WTER has shown consistent growth since the release of its flagship product: Alkaline88(R). Alkaline88 ionized water contains only two ingredients — water and Pink Himalayan rock salt — and has built a reputation for superior hydration with a perfect 8.8 pH balance. The brand was formulated to offer a smooth taste that encourages consumers to drink more and fully hydrate, key factors in maintaining health and wellness,” reads a recent article. “Alkaline88 is now available in more than 75,000 retail stores nationwide, and in addition to being number one in the indie alkaline water space, the brand has captured a prestigious spot as one of the top-10 largest enhanced water brands in the country as well. As per Nielsen data, the brand is the only top-10, nonflavored, value-added water brand that has consistently grown double digits in both units and dollar volume every four-week period since the end of 2019. In addition, research indicates that Alkaline88 has the greatest brand loyalty among alkaline water drinkers.”
To view the full article, visit: https://cnw.fm/SJO2X
About The Alkaline Water Company Inc.
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique, all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products Inc. includes the company’s lab-tested, hemp-extract salves, balms, lotions, essential oils, bath salts, powder packs, oil tinctures, capsules, and gummies. To learn more about the company, visit www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, today announced the successful launch of High Times branded vapes into the Michigan market. Building on RWB’s partnerships and the successful launch of High Times branded packaged flower and pre-rolls earlier in the year, the company is pleased to introduce the High Times branded vapes, offered as premium live resin and distillate cartridges. The High Times branded vapes and previously launched products are available at 22 of Michigan’s finest dispensaries, while the High Times branded product portfolio will be made available to a significant number of the 250+ dispensaries in the state in the second half of 2021. “As I’ve stated before, we look forward to bringing exceptional quality, price and experience through our house of brands and product lines to loyal consumers in Michigan,” said Brad Rogers, RWB’s chairman and CEO. “We have been able to utilize partnerships in Michigan to establish branded product sales and are currently in the final steps of establishing our own operations in Michigan to allow us to utilize all that we have learned and leverage the investments we have made to accelerate that growth.”
To view the full press release, visit https://ibn.fm/rlRup
About Red White & Bloom Brands Inc.
The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Michigan, Illinois, Florida, California, Oklahoma, Arizona, and Massachusetts with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.
NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a provider of virtual and augmented reality (“AR”) experience technologies and services for e-commerce, education, advertising, conferences, and events, recently launched EdTechX. EdTechX is a global higher education solution built on Microsoft Azure and available on Nextech’s LiveX Digital Experience Platform (“DXP”). According to a recent article, EdTechX enables education institutions “to move with the times by transforming traditional learning and event formats into valuable digital experiences.” The solution solves problems previously linked to virtual learning, including the inability to reproduce the sort of instructor-student engagement present in the class environment and the shortcomings of software for conference calls, which cannot provide a personalized experience nor handle large classes. The article quoted Nancy Teodoro, education partner lead at Microsoft (NASDAQ: MSFT) Canada, as saying, “Nextech AR Solutions is helping education institutions digitally transform the way educators teach and the way students learn by enabling remote experiential learning through EdTechX.”
To view the full article, visit https://ibn.fm/fx4Yo
About Nextech AR Solutions Corp.
Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360° portals to its audiences, altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences. Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms, VacuumCleanerMarket.com (“VCM”), InfinitePetLife.com (“IPL”) and TruLyfeSupplements.com (“TruLyfe”), as well as VCM and product sales of residential vacuums, supplies, and parts, and small home appliances sold on Amazon. For more information about the company, visit www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
